Taking HIV treatment exactly as prescribed is key to its effectiveness. This involves not missing doses, taking doses at the right time, and following any instructions about food.

Adherence: latest news

Adherence resources

  • Talking to your doctor

    Taking antiretroviral therapy is a long-term commitment. At present, once you start the drugs, you are likely to be on them for the rest of your life. ...

    From: Booklets

    Information level Level 2
  • Adherence tips

    You may find that a pill box, a phone alarm or a diary helps you with adherence.Adherence can be more challenging when travelling or when...

    From: Factsheets

    Information level Level 2
  • Changing HIV treatment

    Talk to your doctor if you are concerned about any side-effects you are experiencing.If you are having problems taking your HIV treatment, it’s important to be honest...

    From: Factsheets

    Information level Level 2
  • Taking your HIV treatment (adherence)

    Taking your medication exactly as prescribed is key to HIV treatment working.As treatment is a long-term commitment, it’s important that your treatment suits your lifestyle.If you find...

    From: Factsheets

    Information level Level 2
  • Drug resistance

    It's important to always take your HIV treatment at the right times and in the right amounts. If you don't, HIV may become drug resistant.When...

    From: The basics

    Information level Level 1
  • An HIV treatment journey

    This illustrated leaflet shows the journey a lot of people go on with HIV treatment. However, each person’s situation is different. Your own circumstances may...

    From: The basics

    Information level Level 1
  • Taking drugs on time

    For HIV treatment to work well, you need to always take your pills at the right time, without missing any doses.Taking anti-HIV drugs regularly will...

    From: The basics

    Information level Level 1
  • Your diet and anti-HIV drugs

    Choosing a drug combination that you can fit into your existing eating habits is usually easier than trying to adjust your eating habits to fit the drugs. There...

    From: Booklets

    Information level Level 2
  • Travelling with HIV medications – time zone changes

    Travelling to a new time zone may affect when it’s best to take your medication.If you have an undetectable viral load, taking one dose a few hours...

    From: Factsheets

    Information level Level 2
  • Why taking your HIV treatment properly is so important

    The currently available anti-HIV drugs cannot cure HIV. However, treatment with a combination of these drugs (usually three) can reduce the amount of HIV in your blood (your...

    From: Booklets

    Information level Level 2
  • What does taking your HIV treatment involve?

    Taking your drugs as prescribed is often called ‘adherence’. Adherence to your HIV treatment means: Taking all the medicines that make up your...

    From: Booklets

    Information level Level 2
  • Factors that can affect adherence

    Medicines from the three main classes of anti-HIV drugs (nucleoside reverse transcriptase inhibitors or NRTIs; non-nucleoside reverse transcriptase inhibitors or NNRTIs; and protease inhibitors) are available in forms...

    From: Booklets

    Information level Level 2
  • Taking your HIV treatment

    This booklet is a starting point for anyone who wants to know about treatment for HIV. It provides basic information about how HIV treatment works...

    From: Booklets

    Information level Level 2
  • Adherence

    Information on adherence to anti-HIV drugs, including advice on how patients can maintain adherence to their therapy and how healthcare providers can help....

    From: HIV treatments directory

    Information level Level 4

Adherence features

Adherence in your own words

Adherence news from aidsmap

More news

Adherence news selected from other sources

  • 'Emotional closeness’ key to successful HIV treatment support

    The type of relationship someone living with HIV has with both their social network and a nominated ‘treatment partner’ is likely to influence whether they are virally suppressed, research from Botswana suggests.

    15 June 2018 | AVERT
  • Is the World Ready for Long-Acting HIV Treatment?

    "As we look at this question [of] where do long-acting antiretrovirals fit into the armamentarium," commented Carl Dieffenbach, the director of the Division of AIDS within the National Institute of Allergy and Infectious Diseases, "we have to ask ourselves the question: What problems are long-acting or sustained-release formulations solving, and what problems or concerns are the introduction of these type of formulations actually creating?"

    11 June 2018 | The Body Pro
  • Short Cycle ART Noninferior to Continuous Therapy in Youth With HIV

    Short cycle therapy (SCT) comprising an antiretroviral therapy (ART) regime of 5 days on and 2 off achieved sustainable noninferiority of virological suppression in young people with HIV compared with continuous therapy (CT) over a median of 3.6 years, according to research published in PLos One.

    25 May 2018 | Infectious Disease Advisor
  • Smartphone app keeps an 'eye' on daily tuberculosis therapy

    Johns Hopkins researchers report success with a smart phone video-based app that substitutes for a daily in-person visit by a health care worker required for tuberculosis treatment known as directly observed therapy, or DOT. The preliminary study showed that the app may be less costly and may improve privacy concerns raised by patients compared to in-person visits.

    27 April 2018 | Eurekalert Inf Dis
  • Has Anyone Gotten HIV When They Were on PrEP?

    At least 300,000 individuals are now using PrEP worldwide, and only two incidents have been reported where individuals with verified adherence to the drug acquired HIV. Three additional cases have been reported with unconfirmed adherence, and three are currently under investigation.

    22 April 2018 | The Body
  • Uganda:HIV Patients to Get Rewards for Taking ARVs

    Mildmay Uganda and the United States based RAND Corporation yesterday launched a five-year research study of rewarding people living with HIV who take their antiretroviral drugs consistently.

    20 April 2018 | AllAfrica
  • Researchers ID four types of nonbiomedical PrEP failure

    Serota and colleagues describe 14 men who became infected with HIV in their EleMENt study of 300 young BMSM in Atlanta, despite being offered PrEP, along with services to ease access to PrEP uptake. They rightly point out that, in addition to the rare biomedical PrEP failures that receive so much attention at scientific meetings, we should focus our attention on the other “typologies” of PrEP failure that occur once PrEP is offered: low PrEP adherence, PrEP discontinuation, PrEP contemplation without initiation and PrEP refusal.

    14 April 2018 | Healio
  • ARV stock-outs kill more Ugandans

    “Of recent, HIV drug stock-out is adding a lot of misery to us as service providers in the ART clinics because we get very few drugs from National Medical Stores (NMS) which is not enough for our patients. We keep on begging for drugs from nearby health centres. When patients spend long time without taking drugs, they develop resistance,” Dr Peter Andrew Kalema said.

    12 April 2018 | The Observer
  • Violence a major driver for teens not taking their HIV treatment

    Four types of violence were independently associated with adherence – physical abuse by caregivers; witnessing domestic violence; teacher violence; or verbal victimisation by healthcare staff. The researchers comment that violence and victimisation from these sources “evoke a sense of betrayal among adolescents for whom they are hoped-for sources of care and support."

    06 April 2018 | AVERT
  • Disruptions in PrEP adherence provide insights into intimate partner violence

    New study finds strong links between PrEP disruptions and intimate partner violence in Kenya and Uganda. Combined interventions could be key to improving adherence and linking victims to support services.

    02 February 2018 | Avert
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.